Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background Pharmacotherapy remains the mainstay of treatment for acute bipolar mania, but there are many choices, including mood stabilizers (MSs) and antipsychotics (APs). Objective To provide an up-to-date and comprehensive review of the efficacy, acceptability and adverse effects of MSs and APs as combination or augmentation therapy versus monotherapy with either drug class for the treatment of acute mania. Data sources The Cochrane Central Register of Controlled Trials, MEDLINE, PsycINFO, Scopus, and clinical trial databases were searched for articles published between the inception of the databases and July 1, 2014. The following keywords were used: [bipolar disorder, mania, manic, mixed bipolar, schizoaffective] combined with the names of MSs and APs. The reference lists of all the identified randomized controlled trials (RCTs), articles that cited the identified trials, and recent systematic reviews were also checked. Study selection Double-blind RCTs comparing MS and AP as combination or augmentation therapy with either monotherapy during the acute phase treatment of mania were included in the present study. The electronic search yielded 6,445 potential articles in September 2013 and 264 new references in an updated search performed in July 2014. Finally, 19 RCTs were considered eligible for our meta-analyses: MS plus AP combination or augmentation therapy was compared with MS monotherapy in 14 trials (n = 3,651) and with AP monotherapy in 6 trials (n = 606) [one stud…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapy with the atypical antipsychotics quetiapine (level 1), aripiprazole (level 2), risperidone (level 1), or asenapine (level 2) and lithium or divalproex is also recommended as first‐line treatment options with greater efficacy than monotherapy with lithium or divalproex alone, especially in those with higher index severity.144”
In the citing paper
“Trials with paliperidone (level 2 negative) and ziprasidone (level 2 negative) adjunctive therapy to lithium or divalproex showed lack of efficacy.144”
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 2×
“We employed the random-effects model for the metaanalyses [12] because we had anticipated a priori some clinical heterogeneity among the populations and interventions that would be included in this study.”
MethodCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399 · cited 1×
“1 Introduction Bipolar disorder, the eighteenth leading cause of disability in the world [1], is a chronic disorder with an estimated lifetime prevalence of around 1 % [2].”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631 · cited 1×
“Furthermore, a recent multiple-treatments meta-analysis of monotherapy for mania [40] showed that there were no significant differences among these MSs for efficacy or acceptability.”
BackgroundTohen, M., Chengappa, K. N. R., Suppes, T., Zarate, C. A., Calabrese, J. R., Bowden, C. L., Sachs, G. S., Kupfer, D. J., Baker, R. W., Risser, R. C., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.1.62 · Cited by 463
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Trials with paliperidone (Level 2 -ve) and ziprasidone (Level 2 -ve) adjunctive therapy to lithium or divalproex showed lack of efficacy (145).”
BackgroundGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“Most patients included in trials which have compared combination/augmentation therapy versus monotherapy with lithium or valproate had prior treatment with lithium or valproate, whereas most participants in trials com-paring combination/augmentation therapy versus dopamine antagonist as monotherapy had not been on med…”
Fountoulakis, K. Ν., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Kasper, S. F., & Moeller, H. J. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 126
“Meta-analytic studies also suggest that combination treatment is superior to monotherapy at the cost of more frequent adverse events; however, these meta-analyses do not distinguish between add-on and combination studies and populations (Scherk et al., 2007; Smith et al., 2007; Tarr et al., 2011; Ogawa et al., 2014).”
Patel, M. X., Sethi, F. N., Barnes, T. R. E., Dix, R., Dratcu, L., Foex, B. A., Garriga, M., Haste, J. C., Kahl, K. G., Lingford-Hughes, A. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118776738 · Cited by 88
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 77
“Meta-analytic studies also suggest that combination treatment is superior to monotherapy at the cost of more frequent adverse events; however, these meta-analyses do not distinguish between add-on studies (which utilize patients resistant to monotherapy) and combination studies (which utilize general patient populatio…”
Metadata
- Authors
- Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ogawa, Yusuke
- Venue
- CNS Drugs
- Published
- 2014-08-27
- Volume
- 28
- Issue
- 11
- Pages
- 989-1003
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2000154813
- Cited by
- 66
- References
- 37
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 7 · 2022: 9 · 2021: 8 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 1 · 2016: 8 · 2015: 6
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- International Business Machines Corporation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar mania, mood stabilizers, antipsychotic drugs, combination therapy, augmentation therapy, monotherapy, acute mania treatment, treatment response and remission, adverse events, treatment discontinuation
- MeSH terms
- Acute Disease, Bipolar Disorder, Drug Therapy, Combination, Humans, Antipsychotic Agents, Treatment Outcome, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy. https://app.cochat.ai/papers/10.1007/s40263-014-0197-8
- The paper
- Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A. (2014). Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy. CNS Drugs. https://doi.org/10.1007/s40263-014-0197-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.